What is HC Wainwright’s Forecast for DAWN Q1 Earnings?

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) – HC Wainwright reduced their Q1 2026 EPS estimates for Day One Biopharmaceuticals in a research report issued to clients and investors on Wednesday, February 25th. HC Wainwright analyst A. Maldonado now anticipates that the company will earn ($0.11) per share for the quarter, down from their previous estimate of ($0.10). HC Wainwright has a “Buy” rating and a $22.00 price objective on the stock. The consensus estimate for Day One Biopharmaceuticals’ current full-year earnings is ($0.72) per share. HC Wainwright also issued estimates for Day One Biopharmaceuticals’ Q2 2026 earnings at ($0.11) EPS, Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.09) EPS, FY2026 earnings at ($0.41) EPS, FY2027 earnings at $0.10 EPS, FY2028 earnings at $0.04 EPS, FY2029 earnings at $0.57 EPS and FY2030 earnings at $1.05 EPS.

A number of other brokerages have also recently weighed in on DAWN. Wedbush raised their price target on Day One Biopharmaceuticals from $29.00 to $30.00 and gave the company an “outperform” rating in a research report on Wednesday. Needham & Company LLC dropped their target price on shares of Day One Biopharmaceuticals from $18.00 to $17.00 and set a “buy” rating for the company in a report on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a report on Monday, December 29th. Zacks Research lowered shares of Day One Biopharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday. Finally, Piper Sandler raised their price objective on shares of Day One Biopharmaceuticals from $25.00 to $26.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 5th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $26.14.

Day One Biopharmaceuticals Stock Performance

Shares of DAWN stock opened at $10.60 on Friday. The stock has a fifty day moving average price of $10.71 and a 200 day moving average price of $8.80. The stock has a market cap of $1.09 billion, a PE ratio of -10.29 and a beta of -1.26. Day One Biopharmaceuticals has a 1 year low of $5.64 and a 1 year high of $13.20.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.04). The firm had revenue of $53.72 million for the quarter, compared to analysts’ expectations of $49.81 million. Day One Biopharmaceuticals had a negative return on equity of 23.43% and a negative net margin of 67.85%.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Several large investors have recently added to or reduced their stakes in DAWN. Federated Hermes Inc. purchased a new stake in Day One Biopharmaceuticals in the 3rd quarter valued at about $39,000. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Day One Biopharmaceuticals by 26.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,989 shares of the company’s stock worth $46,000 after acquiring an additional 1,029 shares during the last quarter. Ameritas Investment Partners Inc. boosted its position in shares of Day One Biopharmaceuticals by 44.5% in the second quarter. Ameritas Investment Partners Inc. now owns 7,349 shares of the company’s stock worth $48,000 after acquiring an additional 2,264 shares during the last quarter. Quarry LP purchased a new stake in Day One Biopharmaceuticals in the third quarter valued at approximately $49,000. Finally, Entropy Technologies LP acquired a new position in Day One Biopharmaceuticals during the second quarter worth approximately $67,000. 87.95% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Day One Biopharmaceuticals news, insider Michael Vasconcelles sold 2,728 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total value of $31,644.80. Following the completion of the sale, the insider directly owned 4,397 shares of the company’s stock, valued at approximately $51,005.20. The trade was a 38.29% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Lauren Merendino sold 5,814 shares of the stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total value of $67,442.40. Following the transaction, the insider directly owned 60,157 shares in the company, valued at approximately $697,821.20. This represents a 8.81% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 36,461 shares of company stock valued at $422,948 in the last 90 days. Insiders own 6.20% of the company’s stock.

Key Headlines Impacting Day One Biopharmaceuticals

Here are the key news stories impacting Day One Biopharmaceuticals this week:

• Positive Sentiment: Q4 2025 commercial strength and aggressive 2026 guidance — Net product revenues were $52.8M (up ~36% sequentially) and management guided U.S. net product revenues of $225M–$250M for 2026 (midpoint implies ~50% growth over 2025). Company also has several clinical catalysts (Emi‑Le and DAY‑301 readouts in 2026; FIREFLY‑2 possible mid‑2027 readout) that could uplift valuation if positive. Day One Biopharmaceuticals: Commercial Performance With Catalysts Ahead
• Neutral Sentiment: Market sentiment/context — Coverage pieces note improving confidence in broader Nasdaq futures and summarize analyst commentary; these provide background but no single catalyst. DAWN Gaining Confidence In Nasdaq Futures
• Neutral Sentiment: Short‑interest data looks unreliable/insignificant in the latest snapshot (reported 0 shares / data anomalies), so short pressure is not a clear driver today. (No meaningful short‑squeeze signal.)
• Negative Sentiment: Analyst estimate cuts from HC Wainwright — The firm sharply lowered Q1–Q4 2026 and FY2026 EPS forecasts (FY2026 now forecast at -$0.41 vs prior -$0.07) and trimmed out‑year estimates, although it retained a Buy rating and $22 target. The revisions signal weaker near‑term profitability expectations and add downward pressure. HC Wainwright Research Note (DAWN)
• Negative Sentiment: Zacks downgraded DAWN from “strong‑buy” to “hold,” which likely reinforced selling by momentum or quant traders sensitive to rating changes. Zacks Research
• Neutral Sentiment: Analyst roundups (e.g., Benzinga) summarize the mixed views; no single consensus change beyond the above. What Analysts Are Saying About Day One Biopharmaceutical Stock

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.